Drug Trial Radar · NCT05415137
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
268
Actual
Start
Sep 15, 2022
Primary completion
Jun 25, 2025
Study completion Jul 14, 2025
Sponsor
- Lead sponsor
- aTyr Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Kyorin Pharmaceutical Co.,Ltd
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Conditions
- Pulmonary Sarcoidosis
Interventions
Efzofitimod 3 mg/kgDrug
Efzofitimod IV infusion every 4 weeks for a total of 12 doses
Efzofitimod 5 mg/kgDrug
Efzofitimod IV infusion every 4 weeks for a total of 12 doses
PlaceboDrug
Placebo IV infusion every 4 weeks for a total of 12 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean daily oral corticosteroid (OCS) dose at Week 48Time frame: Baseline to Week 48
Locations
91 sites in 9 countries. Site status is shown where the registry gives one.
aTyr Investigative Site
Birmingham, Alabama
aTyr Investigative Site
Phoenix, Arizona
aTyr Investigative Site
Los Angeles, California
aTyr Investigative Site
Sacramento, California
aTyr Investigative Site
Denver, Colorado
aTyr Investigative Site
Washington D.C., District of Columbia
aTyr Investigative Site
Gainesville, Florida
aTyr Investigative Site
Tampa, Florida
aTyr Investigative Site
Weston, Florida
aTyr Investigative Site
Atlanta, Georgia
aTyr Investigative Site
Chicago, Illinois
aTyr Investigative Site
Chicago, Illinois
aTyr Investigative Site
Louisville, Kentucky
aTyr Investigative Site
New Orleans, Louisiana
aTyr Investigative Site
Baltimore, Maryland
aTyr Investigative Site
Boston, Massachusetts
aTyr Investigative Site
Ada, Michigan
aTyr Investigative Site
Detroit, Michigan
aTyr Investigative Site
Minneapolis, Minnesota
aTyr Investigative Site
Rochester, Minnesota
aTyr Investigative Site
Jackson, Mississippi
aTyr Investigative Site
St Louis, Missouri
aTyr Investigative Site
Albany, New York
aTyr Investigative Site
Middletown, New York
aTyr Investigative Site
Durham, North Carolina
aTyr Investigative Site
Greenville, North Carolina
aTyr Investigative Site
Cincinnati, Ohio
aTyr Investigative Site
Cleveland, Ohio
aTyr Investigative Site
Oklahoma City, Oklahoma
aTyr Investigative Site
Portland, Oregon
aTyr Investigative Site
Philadelphia, Pennsylvania
aTyr Investigative Site
Charleston, South Carolina
aTyr Investigative Site
Dickson, Tennessee
aTyr Investigative Site
Dallas, Texas
aTyr Investigative Site
Dallas, Texas
aTyr Investigative Site
Houston, Texas
aTyr Investigative Site
Salt Lake City, Utah
aTyr Investigative Site
Falls Church, Virginia
aTyr Investigative Site
Richmond, Virginia
aTyr Investigative Site
São Bernardo do Campo, Brazil
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.